hENT1 RNA and Protein in Combination May Act as Predictive Biomarkers for Survival for Patients Treated With Adjuvant Gemcitabine in Pancreatic Cancer

被引：0

作者：

Hale, J. ^{[1
]}

Evans, A. ^{[1
]}

Aughton, K. ^{[1
]}

Elander, N. O. ^{[1
,2
]}

Ghaneh, P. ^{[1
]}

Neoptolemos, J. P. ^{[3
]}

Jackson, R. ^{[1
]}

Cox, T. F. ^{[1
]}

Campbell, F. ^{[1
]}

Halloran, C. M. ^{[1
]}

Mackey, J. R. ^{[4
,5
]}

Scarfe, A. G. ^{[4
,5
]}

Valle, J. W. ^{[6
]}

Carter, R. ^{[7
]}

Cunningham, D. ^{[8
,9
]}

Tebbutt, N. C. ^{[10
]}

Goldstein, D. ^{[11
,12
]}

Shannon, J. ^{[13
,14
]}

Glimelius, B. ^{[15
]}

Deakin, M. ^{[16
]}

Charnley, R. M. ^{[17
]}

Anthoney, A. ^{[18
]}

Lerch, M. M. ^{[19
]}

Mayerle, J. ^{[19
,20
]}

Costello, E. ^{[1
]}

Palmer, D. H. ^{[1
]}

Buechler, M. W. ^{[3
]}

Greenhalf, W. ^{[1
]}

机构：

[1] Univ Liverpool, Liverpool Canc Trials Unit, Liverpool, Merseyside, England

[2] Linkoping Univ, Dept Oncol, Linkoping, Sweden

[3] Heidelberg Univ, Dept Surg, Heidelberg, Germany

[4] Cross Canc Inst, Edmonton, AB, Canada

[5] Univ Alberta, Edmonton, AB, Canada

[6] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England

[7] Glasgow Royal Infirm, Glasgow, Lanark, Scotland

[8] Royal Marsden Natl Hlth Serv NHS Fdn Trust, London, England

[9] Royal Marsden Natl Hlth Serv NHS Fdn Trust, Surrey, England

[10] Austin Hlth, Melbourne, Vic, Australia

[11] Univ New South Wales, Prince Wales Hosp, Sydney, NSW, Australia

[12] Univ New South Wales, Sch Clin, Sydney, NSW, Australia

[13] Nepean Canc Ctr, Kingswood, NSW, Australia

[14] Univ Sydney, Sydney, NSW, Australia

[15] Uppsala Univ, Dept Immunol Genet & Pathol, Uppsala, Sweden

[16] North Staffs Univ Hosp, Stoke On Trent, Staffs, England

[17] Freeman Rd Hosp, Newcastle Upon Tyne, Tyne & Wear, England

[18] St James Univ Hosp, Leeds, W Yorkshire, England

[19] Univ Med Greifswald, Dept Med A, Greifswald, Germany

[20] Klinikum LMU Munchen Grosshadern, Med Klin & Poliklin 2, Munich, Germany

来源：

PANCREAS | 2019年 / 48卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：1436 / 1437

页数：2

共 50 条

[1] hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Stina Nordh
Daniel Ansari
Roland Andersson
World Journal of Gastroenterology, 2014, (26) : 8482 - 8490
[2] hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: A systematic review
Nordh, Stina
Ansari, Daniel
Andersson, Roland
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (26) : 8482 - 8490
[3] Predictive value of hENT1 immunohistochemistry for gemcitabine-treated pancreatic cancer is antibody dependent.
Yusuf, Dimas
Lui, Arthur
Abdelaziz, Zainab
Spratlin, Jennifer L.
Mackey, John Robert
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[4] DPD and hENT1 are Not Predictive in Patients with Resected Pancreatic Cancer Treated with Adjuvant S-1 or Gemcitabine Chemotherapy: Collaborative Study of the JASPAC 01 Trial
Okamura, Y.
Yasukawa, S.
Mori, K.
Boku, N.
Akira, F.
Konishi, M.
Morinaga, S.
Toyama, H.
Kaneoka, Y.
Shimizu, Y.
Nakamori, S.
Sata, N.
Kainuma, O.
Kitano, Y.
Sakamoto, H.
Yamaguchi, R.
Hishinuma, S.
Hirano, S.
Yanagisawa, A.
Uesaka, K.
ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S134 - S134
[5] Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
Soichiro Morinaga
Yoshiyasu Nakamura
Takuo Watanabe
Hiroshi Mikayama
Hiroshi Tamagawa
Naoto Yamamoto
Manabu Shiozawa
Makoto Akaike
Shinnichi Ohkawa
Yoichi Kameda
Yohei Miyagi
Annals of Surgical Oncology, 2012, 19 : 558 - 564
[6] Immunohistochemical Analysis of Human Equilibrative Nucleoside Transporter-1 (hENT1) Predicts Survival in Resected Pancreatic Cancer Patients Treated with Adjuvant Gemcitabine Monotherapy
Morinaga, Soichiro
Nakamura, Yoshiyasu
Watanabe, Takuo
Mikayama, Hiroshi
Tamagawa, Hiroshi
Yamamoto, Naoto
Shiozawa, Manabu
Akaike, Makoto
Ohkawa, Shinnichi
Kameda, Yoichi
Miyagi, Yohei
ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S558 - S564
[7] High hENT1 Expression is Predictive of Response of to Adjuvant Gemcitabine for Pancreatic Ductal Adenocarcinoma Patients Randomized to Adjuvant Therapies in the ESPAC Trials
Neoptolemos, J. P.
Cox, T. F.
Greenhalf, W.
Garner, L.
Campbell, F.
Ghaneh, P.
Palmer, D.
Mackey, J.
Dervenis, C.
Scarpa, A.
Bassi, C.
Buechler, M. W.
PANCREAS, 2012, 41 (08) : 1390 - 1390
[8] The association of epithelial expression of hENT1 and survival from adjuvant gemcitabine in pancreatic ductal adenocarcinoma (PDAC).
Renouf, Daniel John
Karasinska, Joanna
Kalloger, Steve
Samimi, Setareh
Peixoto, Renata
O'Connor, Kate
Schaeffer, David
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] The association of epithelial expression of hENT1 and survival from adjuvant gemcitabine in pancreatic ductal adenocarcinoma (PDAC)
Renouf, Daniel John
Karasinska, Joanna
Kalloger, Steve
Peixoto, Renata D'Alpino
O'Connor, Kate
Schaeffer, David
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[10] Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
Greenhalf, William
Ghaneh, Paula
Neoptolemos, John P.
Palmer, Daniel H.
Cox, Trevor F.
Lamb, Richard F.
Garner, Elizabeth
Campbell, Fiona
Mackey, John R.
Costello, Eithne
Moore, Malcolm J.
Valle, Juan W.
McDonald, Alexander C.
Carter, Ross
Tebbutt, Niall C.
Goldstein, David
Shannon, Jennifer
Dervenis, Christos
Glimelius, Bengt
Deakin, Mark
Charnley, Richard M.
Lacaine, Francois
Scarfe, Andrew G.
Middleton, Mark R.
Anthoney, Alan
Halloran, Christopher M.
Mayerle, Julia
Olah, Attila
Jackson, Richard
Rawcliffe, Charlotte L.
Scarpa, Aldo
Bassi, Claudio
Buechler, Markus W.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (01):

← 1 2 3 4 5 →